Aug. 22, 2012 — Sanofi is moving forward with social media efforts for diabetes using its own social media rules in the absence of guidance on the topic from the FDA, according to a Beyond the Pill article discussing a post on Fast Company.
It appears that Sanofi and other companies pursuing social media marketing may have time to experiment with different approaches, as the publication of the document is not imminent. “We are working on the area and
it’s something we feel is important but we don’t
have a specific timeline right now,” Ernest Voyard, senior regulatory council at the FDA’s Office of Prescription Drug Promotion, told Fast Company.
To read the full article, go to: http://beyondthepill.medivo.com/2012/08/sanofi-writing-the-rules-of-social-media/